Dr. James Carroll
James Carroll is an internationally recognized expert in Pho-tobiomodulation (PBM), specializing in beam measurement, PBM dosing, dose-rate effects, and mechanisms of action. He has collaborated with over 50 research institutions worldwide, including Massachusetts General Hospital (MGH), Brigham and Women’s Hospital (BWH), Harvard School of Public Health (HSPH), the Wellman Center for Photomedicine, Stanford Medicine, Penn Dental Medicine, NYU Langone Health, City of Hope, Cedars-Sinai, the Uni-formed Services University, and the UK National Health Service (NHS).
He has co-authored 36 peer-reviewed papers, including eight in collaboration with Harvard-affiliated hospitals and schools, and contributed to five academic books on PBM. His work has helped advance PBM into clinical practice, including its incorporation into the UK National Institute for Health and Care Excellence (NICE) guidelines, where it is recommended for the prevention and treatment of oral mu-cositis within the National Health Service (NHS).
Mr. Carroll has provided expert guidance to policymakers, delivering presentations at the United Nations Global Health Impact Forum, the U.S. Congress on PBM’s role in address-ing the opioid crisis, and advising policy teams at the White House.
He is the Founder, CEO and Chief Science Officer of THOR Photomedicine and a co-founder of Lumithera.
B. Positions, Scientific Appointments, and Honors
2021
T.H. Maiman Award for excellence in medical laser research
2020
World Association for Photobiomodulation Therapy, Presidential Commendation for service and leadership in the field of Photobiomodulation
2013 - To-date
Co-Founder Lumither Inc
1992 - To-date
Founder CEO THOR Photomedicine Ltd
1988 - 1992
Omega Universal Technologies, Photobiomod-ulation equipment sales.
1987 - 1988
Finance for Business, technology grant consul-tancy
1986 - 1987
Pitney Bowes Franking and automated mailing system sales
1984 - 1986
Advanced Power Supplies Works manager
1978 - 1984
Audix Ltd UK various starting in manufacture then test, then production control
OTHER POSITIONS HELD
Biomedical Optics Society - conference chair (2009 - to-date);
Fellow of The Royal Society of Medicine (2009 - to-date);
Editorial Board of Photomedicine and Laser Surgery (2008 to-2013);
World Association for Photobiomodulation Therapy (WALT) board member (2000 - 2004 and 2018 to-date);
North Amer-ican Association for Photobiomodulation board member (2002 - 2006).
Expert reviewer on LLLT/ PBM dose and parameters:
Photobiomodulation Photomedicine & Laser Surgery;
Lasers in Surgery and Medicine;
Lasers in Medical Science;
Photomedicine and Photochemistry;
Journal of Photochemistry and Photobiology;
Annals of Biomedical Engineering;
Public Library of Science (PLoS ONE)
